We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lansoprazole: In the Management of Gastroesophageal Reflux Disease in Children.
- Authors
Scott, L.J.
- Abstract
▴ Lansoprazole, a proton pump inhibitor, inactivates the H/K-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. ▴ After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at baseline were healed (confirmed by endoscopy) and 76% of 62 evaluable children experienced improvements in overall gastroesophageal reflux disease (GERD) symptoms. In this noncomparative trial, 66 children (aged 1-11 years) with GERD with or without esophagitis received oral lansoprazole 15 or 30mg once daily dependent on their weight. ▴ The drug is generally well tolerated in children with GERD. In the largest study, the most common treatment-related adverse events occurring during therapy were constipation and headache.
- Subjects
PROTON pump inhibitors; GASTRIC acid; GASTROESOPHAGEAL reflux
- Publication
Pediatric Drugs, 2003, Vol 5, Issue 1, p57
- ISSN
1174-5878
- Publication type
Article